| Bioactivity | 16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease[1][2][3]. |
| Invitro | 16-HETE (0.01-1 μM) 特异性抑制多形核白细胞聚集和粘附，对血小板功能和血压没有显著影响[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> 16-HETE 相关抗体: |
| In Vivo | 16-HETE (1-20 μg，动脉注射) 在新西兰白兔中立体特异性地 (S-对映异构体) 参与血管舒张、肾灌注调节以及肾小管转运机制[2]。16-HETE (1 μg/kg/min) 可抑制新西兰白兔血栓栓塞性中风模型中的颅内压 (ICP) 升高[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 128914-46-5 |
| Formula | C20H32O3 |
| Molar Mass | 320.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bednar MM, et al., 16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery. 2000 Dec;47(6):1410-8; discussion 1418-9. [2]. Carroll MA, e al., Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996 Oct;271(4 Pt 2):R863-9. [3]. Maciejewska D, et al., Metabolites of arachidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease--A pilot study. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt B):184-9. |